Wednesday, July 22, 2026

pharma · Rheumatoid arthritis · Completely Resected Stage IIB, IIC, and III Melanoma

Celltrion Healthcare Australia

Celltrion Healthcare Australia is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Rheumatoid arthritis, Completely Resected Stage IIB, IIC, and III Melanoma, Previously Untreate

Sydney, AU HQ
9 Employees
TGA registrant Type
Company details
Status
Public
HQ
Sydney, AU
Employees
9
Programs
10
Drugs
30
Patents
0
Clinical program

Trastuzumab

Phase 3 · small molecule · HER2-positive Carcinoma of Breast

Trastuzumab for HER2-positive Carcinoma of Breast is a Phase 3 program (small_molecule) at Celltrion Healthcare Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

Internal code CT-P6 3.2

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Celltrion Healthcare Australia Pty Ltd
Phase
Phase 3
Modality
small_molecule
Indication
HER2-positive Carcinoma of Breast
Status
completed
Trials
1